The latest coronavirus developments and scientific research on prevention and treatment.
Vanda Pharmaceuticals Inc. announced the initiation of clinical study, ODYSSEY VLY-686-3501, in hospitalized patients with COVID-19. The novel SARS-CoV-2 coronavirus is associated with a lower respiratory tract inflammation… read more.
-BD (Becton, Dickinson and Company) , a leading global medical technology company, and BioGX Inc., a molecular diagnostics company, announced that the FDA has granted Emergency Use Authorization… read more.
Novartis announced plans to initiate a Phase III clinical trial in collaboration with Incyte to evaluate the use of Jakavi (ruxolitinib) for treatment of a type of severe… read more.
Chembio Diagnostics, Inc. a leading point-of-care diagnostic company focused on infectious diseases, announced the US launch of the rapid DPP COVID-19 serological point-of-care test for the detection of… read more.
OSE Immunotherapeutics announced that the primary endpoint was met in the predefined Step-1 analysis of its Phase III Atalante 1 clinical trial of Tedopi (T-lymphocyte stimulators) in HLA-A2… read more.
Mallinckrodt Plc and Novoteris, LLC, a clinical stage medical device and pharmaceutical developer focused on innovative nitric oxide gas applications, announced that the Therapeutic Products Directorate Of Health… read more.
Thermo Fisher Scientific Inc announced that it has received the CE mark in the European Union for its diagnostic test to detect nucleic acid from SARS-CoV-2, the virus… read more.
Synairgen plc , the respiratory drug discovery and development company,announces that it has received expedited approvals from the Medicines and Healthcare products Regulatory Agency (MHRA) and Health Research… read more.
Bristol-Myers Squibb Company announced that the FDA approved Zeposia (ozanimod) 0.92 mg for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome,… read more.
Eurobio Scientific announced CE mark approval for its EBX 041 SARS CoV2 proprietary test, developed specifically for the clinical diagnosis of COVID-19. The EBX 041 SARS CoV2 proprietary… read more.
AveXis, a Novartis company, announced a one-time infusion of Zolgensma (onasemnogene abeparvovec-xioi) showed rapid, significant and clinically meaningful therapeutic benefit in patients with spinal muscular atrophy (SMA) across… read more.
Regeneron Pharmaceuticals, Inc. and Sanofi announced they have started a clinical program evaluating Kevzara (sarilumab) in patients hospitalized with severe COVID-19 infection . Kevzara is a fully-human monoclonal… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
